The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Needham analyst Serge Belanger named Liquidia (LQDA) a top pick for 2025 with a Buy rating and $19 price target The stock was also the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback